Search results for "Severity of illne"

showing 4 items of 1114 documents

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

2022

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-alpha therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab. Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection. Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline an…

reactivationBiologicpsoriasis.latent tuberculosis infectionsecukinumabchemoprophylaxisDermatologyBiologicsBiologics; chemoprophylaxis; latent tuberculosis infection; psoriasis; reactivation; secukinumab.Antibodies Monoclonal HumanizedSeverity of Illness IndexTreatment OutcomeLatent TuberculosisIsoniazidHumansPsoriasisTuberculosisRifampinchemoprophylaxiRetrospective Studiespsoriasi

researchProduct

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GI…

2007

OBJECTIVE: To assess the prevalence of good clinical response and remission in rheumatoid arthritis (RA) patients with longstanding disease treated with anti-tumor necrosis factor-alpha (TNF-alpha) drugs at outpatient clinics. METHODS: Retrospective national study of 14 academic tertiary referral rheumatology medical centers. RA patients with a Disease Activity Score (DAS28) > 3.2 were defined as having active disease and could start TNF-alpha blockers. All patients received one TNF-alpha blocker plus methotrexate (10-20 mg/wk). At the third month the patients were categorized as responders or nonresponders, based on improvement of at least 0.25 of the Health Assessment Questionnaire (HAQ).…

rheumatoid arthritisAdultMaleQuality Assurance Health Carepredictors of remissionTumor Necrosis Factor blockersAntibodies Monoclonal HumanizedSeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptArthritis RheumatoidRheumatoid arthritis; Good clinical response; Tumor Necrosis Factor blockersPredictive Value of TestsHumansRheumatoid arthritispredictors of remission; rheumatoid arthritis; tumor necrosis factor-alpha blockersAgedRetrospective StudiesGood clinical responseTumor Necrosis Factor-alphatumor necrosis factor-alpha blockersRemission InductionAdalimumabAntibodies MonoclonalMiddle AgedPrognosisInfliximabLogistic ModelsMethotrexateTreatment Outcomedisability score; good clinical response; remission; rheumatoid arthritis; tumor necrosis factor-α blockersItalyAntirheumatic AgentsImmunoglobulin GFemale

researchProduct

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

2020

To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies publishe…

severe asthmamedicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 Severe Asthma Network in Italy inflammationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaPopulationImmunologyMEDLINEOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioNOInternal medicineDiabetes mellitusSeverity of illnessmedicineImmunology and AllergyRisk factorLetters to the EditoreducationLetter to the EditorAsthmaeducation.field_of_studybusiness.industryIncidence (epidemiology)Mortality rateCOVID-19medicine.diseaseComorbiditySevere Asthma Network in ItalyinflammationCohortbusinessMepolizumabmedicine.drug

researchProduct

Immune responses during COVID-19 infection

2020

International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually m…

researchProduct